Your browser doesn't support javascript.
loading
Biological variation of PIVKA-II in blood serum of healthy subjects measured by automated electrochemiluminescent assay.
Jabor, Antonín; Kubícek, Zdenek; Cásenská, Jitka; Vacková, Tereza; Filová, Vanda; Franeková, Janka.
Afiliação
  • Jabor A; Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídenská 1958/9, 140 21, Praha 4, Czech Republic.
  • Kubícek Z; Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Praha 10, Czech Republic.
  • Cásenská J; Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídenská 1958/9, 140 21, Praha 4, Czech Republic.
  • Vacková T; Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídenská 1958/9, 140 21, Praha 4, Czech Republic.
  • Filová V; Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Praha 10, Czech Republic.
  • Franeková J; Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídenská 1958/9, 140 21, Praha 4, Czech Republic.
Pract Lab Med ; 39: e00389, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38576474
ABSTRACT

Background:

Prothrombin/Protein Induced by Vitamin K Absence-II (PIVKA-II) is a candidate biomarker of hepatocellular cancer, recommended both for diagnostics and monitoring. The aim was to evaluate biological variation (BV) of serum PIVKA-II.

Methods:

Within-subject (CVI) and between-subject (CVG) BV estimates were assessed in 14 healthy volunteers in a 6-week protocol. Serum concentrations of PIVKA-II were measured by a Roche Elecsys PIVKA-II diagnostic kit (cobas e8000). Precision (CVA) was assessed from duplicate measurements of all volunteers' samples. Two methods were used for the estimation of CVI SD-ANOVA and CV-ANOVA method. We calculated the index of individuality (II) and reference change value. The experiment was fully compliant with EFLM database checklist.

Results:

The CVI of PIVKA-II in healthy persons, as calculated by two statistical methods, were 8.2% (SD-ANOVA with CVA of 3.2%) and 9.4% (CV-ANOVA) with CVA of 2.7%). The CVG was 19.5% (SD-ANOVA), and respective II and RCV were 0.42 and 24.4%.

Conclusions:

CVI and CVG of PIVKA-II were 8.2% and 19.5%, respectively, with CVA below 4%. The low II and RCV below 25% enable the use of this biomarker both for diagnostics and monitoring. More data are needed before the introduction of PIVKA-II into clinical practice.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Pract Lab Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: República Tcheca

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Pract Lab Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: República Tcheca